Propensity score weighted multi‐source exchangeability models for incorporating external control data in randomized clinical trials

Author:

Wei Wei1ORCID,Zhang Yunxuan1,Roychoudhury Satrajit2ORCID,

Affiliation:

1. Department of Biostatistics Yale School of Public Health New Haven Connecticut

2. Global Biometrics & Data Management Pfizer Inc New York New York USA

Abstract

Among clinical trialists, there has been a growing interest in using external data to improve decision‐making and accelerate drug development in randomized clinical trials (RCTs). Here we propose a novel approach that combines the propensity score weighting (PW) and the multi‐source exchangeability modelling (MEM) approaches to augment the control arm of a RCT in the rare disease setting. First, propensity score weighting is used to construct weighted external controls that have similar observed pre‐treatment characteristics as the current trial population. Next, the MEM approach evaluates the similarity in outcome distributions between the weighted external controls and the concurrent control arm. The amount of external data we borrow is determined by the similarities in pretreatment characteristics and outcome distributions. The proposed approach can be applied to binary, continuous and count data. We evaluate the performance of the proposed PW‐MEM method and several competing approaches based on simulation and re‐sampling studies. Our results show that the PW‐MEM approach improves the precision of treatment effect estimates while reducing the biases associated with borrowing data from external sources.

Funder

National Cancer Institute

National Institute of Dental and Craniofacial Research

Publisher

Wiley

Reference37 articles.

1. US Food and Drug Administration.Rare diseases: natural history studies for drug development guidance for industry.https://www.fda.gov/media/122425/download2019.

2. Use of real‐world evidence in regulatory decisions for rare diseases in the United States—Current status and future directions

3. Advancing innovative clinical trials to efficiently deliver medicines to patients

4. Real-World Evidence and Real-World Data for Evaluating Drug Safety and Effectiveness

5. US Food and Drug Administration.Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products.https://www.fda.gov/media/164960/download

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3